Navigation Links
Landauer, Inc. Reports Fiscal 2013 First Quarter Results
Date:2/11/2013

GLENWOOD, Ill., Feb. 11, 2013 /PRNewswire/ -- Landauer, Inc. (NYSE: LDR), a recognized leader in personal and environmental radiation measurement and monitoring, outsourced medical physics services and high quality medical consumable accessories, today reported financial results for its fiscal 2013 first quarter ended December 31, 2012.

Fiscal 2013 First Quarter Highlights

  • Revenue of $36.7 million in the first quarter of fiscal 2013
  • First fiscal quarter 2013 operating income of $6.7 million includes IT platform enhancement expense ($1.2 million) and non-cash stock based compensation ($0.7 million)
  • Net income of $4.9 million, or $0.52 per diluted share, included $0.06 per diluted share of IT platform enhancement, and non-cash stock based compensation expenses
  • EBITDA of $11.5 million for fiscal 1Q13
  • Company continued successful stabilization of IT platform following fiscal 4Q12 launch
  • Company reaffirms fiscal 2013 guidance
  • "During the quarter, we focused on several strategic initiatives to further our competitive positioning and long-term growth.  Our IT systems initiative is well into the stabilization phase after a successful launch and opportunities in the military and emergency response markets have continued to expand with Radwatch system revenue in the quarter," said Bill Saxelby, President and CEO of Landauer. "We continued to make investments in technology which we believe will lead to new growth opportunities and we strengthened our human capital across a variety of key functions. These strategic efforts during the quarter, combined with our expectations and the opportunities that we see over the remainder of the year, leave us well positioned to achieve our fiscal 2013 guidance."

    First Fiscal Quarter Financial Overview and Business Segment ResultsRevenues for the first fiscal quarter of 2013 were $36.7 million.  The Medical Physics segment and the Medical Products segment contributed an increase of $0.2 million and $0.5 million, respectively due to their acquisitions over prior year.  The Radiation Measurement segment experienced a decrease of $0.6 million.  Revenue in the quarter included $1.7 million of Radwatch System sales, primarily to the U.S. military, while the prior year included the benefit of $2.0 million in InLight equipment sales into the military market.  Consolidated revenue in the quarter was negatively affected $0.2 million by currency fluctuation, as compared with the prior year period, principally due to weakness in the Euro and Real against the U.S. dollar.

    Gross margins were 54.8 percent for the first fiscal quarter of 2013, compared with 59.3 percent for the first fiscal quarter of 2012. The decrease in the gross margin was primarily due to higher costs associated with the new IT platform enhancement, as a portion of depreciation is now allocated to cost of sales since the project went operational during the fiscal fourth quarter of 2012, representing $0.5 million increase; as previously capitalized investment began its scheduled depreciation with a portion related to manufacturing production being allocated in cost of sales.  Additional cost of sales in the quarter includes $0.4 million of ongoing IT system support expenses, over the prior year fiscal quarter. In addition, in the prior fiscal year quarter the Medical Physics segment had a significant level of commissioning sales, which are episodic in nature with that business operating on a relative fixed margin model. 

    Total selling, general and administrative expenses for the first fiscal quarter of 2013 were $13.4 million, an increase of $1.0 million, or 8.3 percent, compared to $12.4 million for the same quarter in fiscal 2012.
    For the first fiscal quarter of 2013, total selling, general and administrative included $0.7 million IT platform enhancement and $0.7 million of non-cash stock based compensation expenses. This compares with the $12.4 million reported for the first fiscal quarter of 2012, while the current quarter reflects $0.5 million increase in customer service related expenses and $0.3 million increase in IT platform enhancement related expenses.  The prior year first fiscal quarter of 2012 included $0.8 million of non-cash stock based compensation related expenses.  During the fourth quarter of 2012 the IT platform enhancement project successfully went operational and the balance of the above mentioned capitalized investment began its scheduled depreciation with a portion related to the non-manufacturing portion allocated to SG&A expenses, an increase of $0.3 million.

    Operating income for the first fiscal quarter of 2013 was $6.7 million, a decrease of $0.9 million, or 11.8 percent compared with operating income of $7.6 million for the same quarter in fiscal 2012. Operating income, adjusted for non-recurring acquisition and reorganization expenses, IT platform enhancement related expenses, and non-cash stock based compensation expenses, for the first fiscal quarter of 2013 was $7.6 million, a 27.5 percent decrease, compared with adjusted operating income on a relative basis of $10.5 million for the first fiscal quarter of 2012.

    Interest expense, net of investment income in the quarter, increased $0.4 million associated with borrowings to acquire IZI in the first fiscal quarter of 2012.

    The effective tax rate for the first fiscal quarter of 2013 and 2012 was 31.1 percent and 35.0 percent, respectively. The decrease in effective tax rate was due primarily to a change in the mix of earnings based on geographic location of the Company's operations in various jurisdictions and the specific legal entities subject to taxation in those jurisdictions.

    Net income for the first fiscal quarter ended December 31, 2012 was $4.9 million, or $0.52 per diluted share, which is consistent with the first fiscal quarter of 2012.

    EBITDA for the fiscal first quarter 2013 was $11.5 million compared with $10.6 million in the comparable prior year period. The increase was due primarily to additional interest expense and depreciation offset slightly by lower tax expense.  Adjusted EBITDA was $12.4 million compared to the prior year period Adjusted EBITDA of $13.5 million. A reconciliation of net income to EBITDA and Adjusted EBITDA is included in the attached financial exhibits.

    Radiation Measurement SegmentRadiation Measurement revenues for the first fiscal quarter of 2013 decreased 2.2 percent, or $0.6 million, from the first fiscal quarter of 2012 to $26.4 million.  The decrease in the quarter was primarily due to decreases at international subsidiaries over prior year first fiscal quarter.

    Radiation Measurement operating income for the first fiscal quarter of 2013 decreased to $5.3 million, or 16.3 percent, from $6.3 million in the comparable prior year period.  The decrease in operating income was due to increased IT expenses related to the company's IT platform enhancement of $1.2 million, decreased revenues from international subsidiaries of $0.4 million, additional customer service support of $0.5 million, additional manufacturing costs of $0.4 million, which was offset by prior year first quarter acquisition costs of $1.8 million.  Corporate expenses for shared functions are recognized in the Radiation Measurement segment where they have been reported historically.  Acquisition and reorganization costs are not allocated to the segments.  As the Company's business model evolves in increased complexity, management may determine it necessary to change this reporting practice to reflect any appropriate allocations.

    Medical Physics SegmentMedical Physics revenues for the first fiscal quarter of 2013 increased 2.0 percent, or $0.2 million, from the comparable period in fiscal 2012 to $7.6 million due to the impact of acquired companies.  The Medical Physics segment operating income was $0.8 million, or 10.4 percent of revenues, as compared to $0.9 million, or 12.0 percent of revenues, in the first fiscal quarter of 2012. 

    Medical Products Segment
    Medical Products revenues for the first fiscal quarter of 2013 increased 22.7 percent, or $0.5 million, from the first fiscal quarter of 2012 to $2.7 million. Medical Products operating income for the first fiscal quarter of 2013 was $0.7 million, or 24.9 percent of revenues, as compared to $0.4 million, or 16.7 percent of revenues, in the first fiscal quarter of 2012.  The increase in revenue and operating income is due primarily to a full quarter results in fiscal 2013 versus only 1.5 months in fiscal 2012.

    Balance SheetLandauer ended the first fiscal quarter of 2013 with total assets of $300.8 million, a decrease of $1.3 million compared to total assets of $302.1 million at the end of fiscal 2012.  The Company completed the quarter with $16.5 million of cash and cash equivalents on the balance sheet and unused borrowing capacity of $29.2 million under its current $175 million credit facility, which provides adequate liquidity to meet its current and anticipated obligations.  Net operating cash flow generated during the first fiscal quarter of 2013 was $2.1 million.Fiscal 2013 OutlookLandauer's business plan for fiscal 2013 currently anticipates aggregate revenues for the year to be in the range of $164 to $168 million.  The business plan also anticipates a blended effective tax rate for the full fiscal year in the range of 32 percent to 35 percent.

    Based upon the above assumptions, the Company anticipates reported net income for fiscal 2013 in the range of $21 to $23 million and Adjusted EBITDA expected for fiscal 2013 in the range of $55 to $58 million.

    Conference Call DetailsLandauer has scheduled its first quarter conference call for investors over the Internet on Tuesday, February 12, 2013, at 9:00 a.m. Central Time (10 a.m. Eastern Time).  To participate, callers should dial 877-941-0843 (within the United States and Canada), or 480-629-9819 (international callers) about 10 minutes before the presentation.  To listen to a webcast on the Internet, please go to the Company's website at http://www.landauerinc.com at least 15 minutes early to register, download and install any necessary audio software.  Investors may access a replay of the call by dialing 800-406-7325 (within the United States and Canada), or 303-590-3030 (international callers), passcode 4594725#, which will be available through Tuesday, March 12, 2013.  The replay will also be available on Landauer's website for 90 days following the call.

    About LandauerLandauer is a leading global provider of technical and analytical services to determine occupational and environmental radiation exposure, the leading domestic provider of outsourced medical physics services, as well as a provider of high quality medical accessories used in radiology, radiation therapy, and image guided surgery procedures.  For more than 50 years, the Company has provided complete radiation dosimetry services to hospitals, medical and dental offices, universities, national laboratories, nuclear facilities and other industries in which radiation poses a potential threat to employees.  Landauer's services include the manufacture of various types of radiation detection monitors, the distribution and collection of the monitors to and from customers, and the analysis and reporting of exposure findings.  The Company provides its dosimetry services to approximately 1.8 million individuals globally.  In addition, through its Medical Physics segment, the Company provides therapeutic and imaging physics services to the medical physics community. Through its Medical Products segment, the Company provides medical consumable accessories used in radiology, radiation therapy, and image guided surgery procedures.

    Safe Harbor StatementSome of the information shared here (including, in particular, the section titled "Fiscal 2013 Outlook") constitutes forward-looking statements that are based on assumptions and involve certain risks and uncertainties.  These include the following, without limitation: assumptions, risks and uncertainties associated with the Company's future performance, the Company's development and introduction of new technologies in general; the ability to protect and utilize the Company's intellectual property; continued customer acceptance of the InLight technology; the adaptability of optically stimulated luminescence (OSL) technology to new platforms and formats; military and other government funding for the purchase of certain of the Company's equipment and services; the impact on sales and pricing of certain customer group purchasing arrangements; changes in spending or reimbursement for medical products or services; the costs associated with the Company's research and business development efforts; the usefulness of older technologies and related licenses and intellectual property; the effectiveness of and costs associated with the Company's IT platform enhancements; the anticipated results of operations of the Company and its subsidiaries or ventures; valuation of the Company's long-lived assets or business units relative to future cash flows; changes in pricing of products and services; changes in postal and delivery practices; the Company's business plans; anticipated revenue and cost growth; the ability to integrate the operations of acquired businesses and to realize the expected benefits of acquisitions; the risks associated with conducting business internationally; costs incurred for potential acquisitions or similar transactions; other anticipated financial events; the effects of changing economic and competitive conditions, including instability in capital markets which could impact availability of short and long-term financing; the timing and extent of changes in interest rates; the level of borrowings; foreign exchange rates; government regulations; accreditation requirements; changes in the trading market that affect the costs of obligations under the Company's benefit plans; and pending accounting pronouncements.  These assumptions may not materialize to the extent assumed, and risks and uncertainties may cause actual results to be different from what is anticipated today.  These risks and uncertainties also may result in changes to the Company's business plans and prospects, and could create the need from time to time to write down the value of assets or otherwise cause the Company to incur unanticipated expenses.  Additional information may be obtained by reviewing the information set forth in Item 1A "Risk Factors" and Item 7A "Quantitative and Qualitative Disclosures about Market Risk" and information contained in the Company's Annual Report on Form 10-K for the year ended September 30, 2012 and other reports filed by the Company, from time to time, with the Securities and Exchange Commission.  The Company does not undertake, and expressly disclaims, any duty to update any forward-looking statement whether as a result of new information, future events or changes in the Company's expectations, except as required by law.

    During the past several years, the Company has been engaged in an initiative to re-engineer many of its business processes and replace significant components of its information technology systems.  A principal component of this initiative is the implementation of new enterprise resource planning software and other applications to manage certain business operations.  This enhancement of the Company's IT platform has been a complex project and has involved extensive customization of the Company's software and IT systems.  In July 2012, the enhanced IT platform became operational.  Although the Company has been encouraged by its experience with the enhanced platform during the first few months of the platform's start-up phase, there can be no assurance that, during the remainder of this start-up phase, the new platform will continue to maintain its functionality at the levels anticipated or otherwise meet the Company's business and operational objectives.  If unforeseen problems arise, the Company's operations could be adversely impacted, including the ability of the Company to perform one or more of the following in a timely manner: customer quotes, customer orders, product shipment, customer services and support, order billing and tracking, contractual obligations fulfillment and related operations.  As previously disclosed, the Company expects to incur ongoing maintenance expenditures for the new IT platform at levels higher than the Company traditionally experienced under its prior platform.  Unforeseen problems with the new platform could increase further such expenditures.

    Financial Tables Follow 

     Landauer, Inc. and Subsidiaries First Fiscal Quarter 2013 Consolidated Statements of Income (Unaudited)Three Months EndedDecember 31,(Dollars in Thousands, Except per Share)20122011Net revenues

    $

    36,681$

    36,669Costs and expenses:Cost of sales16,56314,906Selling, general and administrative13,39112,361Acquisition and reorganization costs01,849Costs and expenses29,95429,116Operating income6,7277,553Equity in income of joint ventures1,528804Interest income (expense), net(1,033)(590)Other income (expense), net9559Income before taxes7,3177,826Income taxes2,2742,742Net income5,0435,084Less:  Net income attributed to noncontrolling interest166159Net income attributed to Landauer, Inc.

    $

    4,877$

    4,925Net income per share attributable to Landauer, Inc. shareholders:Basic

    $

    0.52$

    0.52Weighted average basic shares outstanding9,3369,348Diluted

    $

    0.52$

    0.52Weighted average diluted shares outstanding9,3859,385Dividends paid per share

    $

    0.55$

    0.55 

     Landauer, Inc. and Subsidiaries Consolidated Balance Sheets (Unaudited)(Dollars in Thousands)December 31,2012September 30,2012ASSETSCurrent assets:Cash and cash equivalents

    $

    16,497$

    17,633Receivables, net of allowances of $1,163 and $1,088,  respectively36,39135,165Inventories9,1998,638Prepaid income taxes6982,148Prepaid expenses and other current assets4,4883,975Current assets67,27367,559Property, plant and equipment, at cost103,330101,375Accumulated depreciation and amortization(49,125)(46,983) Net property, plant and equipment54,20554,392Equity in joint ventures22,66424,108Goodwill107,001106,717Intangible assets, net of accumulated amortization of $10,553 and $9,696, respectively36,79337,402Dosimetry devices, net of accumulated depreciation of $9,316 and $8,879, respectively6,5376,189Other assets (Note 4)6,3665,758Assets

    $

    300,839$

    302,125LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable

    $

    6,637$

    9,656Dividends payable5,3425,345Deferred contract revenue15,06514,947Accrued compensation and related costs5,5208,260Other accrued expenses7,2157,096Current liabilities39,77945,304Non-current liabilities:Long-term debt145,847141,347Pension and postretirement obligations (Note 6)17,69017,586Deferred income taxes15,74515,733Other non-current liabilities9981,053Non-current liabilities180,280175,719Stockholders' equity:Preferred stock, $.10 par value per share, authorized 1,000,000 shares; none issued00Common stock, $.10 par value per share, authorized 20,000,000 shares; 9,551,079 and 9,493,368 shares issued and outstanding at December 31, 2012and September 30, 2012, respectively955949Additional paid in capital36,58735,898Accumulated other comprehensive loss(5,788)(5,272)Retained earnings47,79348,142Landauer, Inc. stockholders' equity79,54779,717Noncontrolling interest1,2331,385Stockholders' equity80,78081,102Liabilities and Stockholders' Equity

    $

    300,839$

    302,125 Reconciliation of Net Income to Adjusted Earnings before Interest, Taxes, Depreciation and AmortizationThree Months EndedDecember 31,20122011Net income attributed to Landauer, Inc.

    $

    4,877$

    4,925Add back:Interest expense, net932528Depreciation and amortization3,4502,356Provision for income taxes2,2742,742Earnings before interest, taxes, depreciation and amortization (EBITDA)

    $

    11,533$

    10,551Adjustments:Non-cash stock-based compensation expense684830IT platform enhancements expenses178282Acquisition and reorganization costs01,849Sub-total adjustments8622,961Adjusted EBITDA

    $

    12,395$

    13,512 Reconciliation of EPS to Adjusted EPSThree Months EndedDecember 31,20122011Net income attributed to Landauer, Inc.

    $

    4,877$

    4,925Sub-total adjustments8622,961Income taxes on adjustments(268)(1,036) Adjustments, net5941,925Adjusted Net Income

    $

    5,471$

    6,850Adjusted Net Income per Diluted Share

    $

    0.58$

    0.73 Adjusted Free Cash FlowThree Months EndedDecember 31,20122011Adjusted EBITDA

    $

    12,395$

    13,512Change in working capital(6,429)2,285Capital expenditures(1,902)(3,839)Adjusted Free Cash Flow

    $

    4,064$

    11,958 


    '/>"/>
    SOURCE Landauer, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. Landauer, Inc. Reports Fiscal 2012 Fourth Quarter And Year End Results
    2. Landauer, Inc. Sets Date And Time For Announcement Of Fiscal Fourth Quarter And Full Year 2012 Results
    3. Landauer, Inc. Appoints Ronald Zilkowski To Vice President, Corporate Controller And Chief Accounting Officer
    4. Landauer, Inc. Appoints Peter Cempellin To President Of Landauer Radiation Measurement
    5. Landauer, Inc. Reports Fiscal 2012 Second Quarter Results
    6. Allied Healthcare Products Reports Second Quarter Loss
    7. Medical Devices Research: Country Reports on Market Profile, Competitive Environment and more at RnRMarketResearch.com
    8. Pharmaceutical Market & Biotechnology Industry 2013 Outlook in New Research Reports at ReportsnReports.com
    9. Misonix Reports Financial Results for First Half of Fiscal 2013
    10. CareFusion Reports First Half Fiscal 2013 Results
    11. Avanir Pharmaceuticals Reports Fiscal 2013 First Quarter Financial And Business Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
    (Date:6/26/2016)... June 26, 2016 Story ... operating models within the health care industry is causing ... efficiency , Deloitte offers a suite of solutions ... issues impacting efficient cost optimization: labor resource analysis, revenue ... services facilitate better outcomes and better economics ...
    (Date:6/24/2016)... June 24, 2016  Collagen Matrix, Inc., ("Collagen ... and manufacturing of collagen and mineral based medical ... that Bill Messer has joined the ... further leverage the growing portfolio of oral surgery, ... Bill joins the Collagen Matrix executive team ...
    Breaking Medicine Technology:
    (Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star ... , Millions of individuals in the United States and Canada wear eyeglasses. Once considered ... both correct vision and make a fashion statement. Even celebrities use glasses as a ...
    (Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
    (Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
    (Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
    (Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
    Breaking Medicine News(10 mins):